Compound class:
Synthetic organic
Comment: PN10 is a ponatinib/necrostatin hybrid molecule that inhibits RIPK1-driven necroptosis [1]. The compound retains most of ponatinib's in vivo activity, but with improved selectivity conferred by the necrostatin component.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Immunopharmacology Comments |
Although use of ponatinib is associated with significant safety concerns and would not be considered for more general use as an anti-inflammatory agent, ponatinib-derived analogues such as PN10 could be evaluated for clinical benefit for a cancer-associated inflammation. |